Genentech's Ocrelizumab was just approved AND they priced it 25% lower than Aubagio, or Lemtrada. Efficacy was as good as Lemtrada and their PI was almost the ideal case in terms of safety content. Genzyme's MS franchise has long been a joke run by untalented people who don't work hard. Was only saved by over-promise blowback from Tecfidera plateau'ing. Aubagio is still barely better than a placebo sugar pill, in terms of efficacy, and nobody wants all the side effects of Lemtrada
aub side effects are terrible. Only reason it's gaining a lil traction is pml hasn't been an issue like the other two orals. Otherwise, it's efficacy is like a platform, with pregnancy issues, hairloss, liver concerns, and doesn't do much for cutting relapses.
Well your no PML story is over kids. Poster being done at ECTRIMS will show what a toxic, poor efficacy, crap product Aubagio truly is..... can't blame Tysabri seeing the titters were so low.
This thread is truly silly. Here we are 2 years later stronger than ever- even in light of new competitors. Both products are truly unique and not going anywhere.
Not Mavenclad, but it’s own safety profile. If you sell Lemtrada, it’s a good time to dust off the resume. Covid speeding up its end.